The recent shift toward legalization has not been enough to undo the racism endemic to U.S. cannabis policy. The authors lay out policies to improve equity and erase the racist legacy of prohibition.
Katharine Neill Harris, William MartinOctober 1, 2021
This study finds that Maryland's all-payer model for healthcare comparatively lowered the risk of complications from surgery, as well as reducing increases in associated costs.
Anaeze C. Offodile II, Oluseyi Aliu, Andrew W. P. Lee, Jonathan E. Efron, Robert S. D. Higgins, Charles ButlerSeptember 28, 2021
This journal article explores why the public and stakeholders should help develop guidelines and policies governing scientific practices for controversial biomedical research issues, such as genetically editing human embryos.
Kirstin R.W. Matthews, Ana S. Iltis, Sarah HooverSeptember 22, 2021
The authors sought to develop and test a tool that accurately predicts the unique financial burden to individual patients undergoing treatment for breast cancer. JCO Clinical Cancer Informatics, an American Society of Clinical Oncology Journal
Anaeze C. Offodile II, Chris Sidey-Gibbons, André Pfob, Malke Assad, Stefanos Boukovalas, Yu-Li Lin, Jesse Creed Selber, Charles ButlerMarch 26, 2021
The global financial cost of Covid-19 could top $15 trillion. But governments could prevent future pandemics by investing as little as $22 billion a year in programs to curb wildlife trafficking and stem the destruction of tropical forests, according to an international team of scientists including Baker Institute Faculty Scholar Ted Loch-Temzelides.
Ted Loch-Temzelides, Andrew Dobson, Stuart Pimm, Lee Hannah, Les Kaufman, Jorge Ahumada, Amy Ando, Aaron Bernstein, Jonah Busch, Peter Daszak, Jens Engelmann, Margaret Kinnaird, Binbin Li, Thomas Lovejoy, Katarzyna Nowak, Patrick Roehrdanz, Mariana ValeJuly 24, 2020
The authors examine the relationship between market competition and the use of surgical services for cancer to test the theory that market competition promotes patient access and health care delivery.
Marcelo Cerullo, Clara Lee, Anaeze C. Offodile IIDecember 1, 2018
Regenerative medicine and stem cell research are exciting new fields. But as the fields progress toward clinical therapies, controversies emerge. Hype surrounding stem cell research has caused an increase in their use in interventions that are not clinically proven. Furthermore, the regulatory agencies have a lot of difficulty dealing with cell therapies, which are distinctly different from drugs and medical devices they more commonly approve. To move the field forward, advocates, regulators and scientists need to come together to find new options for stem cell research oversight that protects both the patients and the research field.
Biotechnology scientists must be aware of the broad patent landscape and push for new patent and licensing guidelines, according to a new paper from the Baker Institute.
